Seeking Alpha

GERN
Geron Corporation

5/26/2012, 8:33 AM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GERN Market Currents more »
  • May 2 Geron (GERN): Q1 EPS of -$0.15 beats by $0.03. Revenue of $1.3M beats by $810K. (PR)
    Comment!
    [Earnings]
GERN in Focus more »
GERN Press Releases and Filings more »
GERN Instablog posts more »
  • Advanced Cell Technologies - Can Stem Cell Technology Change The Face Of Medicine?
    Tue, May 1 • Jason Boyce • Comment!
  • Healthcare Conferences and News: Week of 1/9 to 1/13
    Fri, Jan 13 • CrystalResearch • 2 Comments
  • New CFO Headlines a Series of Executive Suite Changes at Geron
    Fri, Jan 6 • Disclosure Insight • Comment!
  • Analyst Interview on International Stem Cell Corp.
    Tue, Jul 26, 2011 • Jason Napodano • Comment!
  • 20 Optionable Cancer Stocks Trading with Values >Spectrum Pharma => Rx Investors.com
    Mon, Jan 3, 2011 • Justin M. Hall • Comment!
Write a post on GERN
GERN StockTalks
GERN vs. ETF Alternatives
Company Description

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple... More

Sector: Healthcare
Industry: Biotechnology
Country: United States